On October 13, 2026, Drugs Made In America Acquisition Corp. (the “Company”) and Power Analytics Global Corp, a Delaware corporation (“PAGC”), entered into Amendment No. 1 (the “Amendment”) to their Amended and Restated Definitive Merger Agreement dated as of September 8, 2026 (the “Merger Agreement”). The Amendment was approved by the boards of directors of both parties.
Standalone Closing Valuation
The Merger Agreement provides for a Closing Valuation of US$2,850,000,000, determined on an asset basis and including PAGC’s proposed acquisition of APQC Inc and the UltraSolar intellectual property (the “APQC Acquisition”), and makes completion of the APQC Acquisition a condition to closing.